During a Phase II clinical trial (CRESTONE trial, NCT04383210), this anti-ERBB3 IgG2 monoclonal antibody produced an ORR of 33% across various tumor types harboring NRG1 fusions (20). Here, ERBB3 is linked to neoplasm.